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Global genetic variation of select opiate metabolism genes in
self-reported healthy individuals
FR Wendt1, G Pathak1, A Sajantila2, R Chakraborty1 and B Budowle1,3,4
CYP2D6 is a key pharmacogene encoding an enzyme impacting poor, intermediate, extensive and ultrarapid phase I metabolism
of many marketed drugs. The pharmacogenetics of opiate drug metabolism is particularly interesting due to the relatively high
incidence of addiction and overdose. Recently, trans-acting opiate metabolism and analgesic response enzymes (UGT2B7, ABCB1,
OPRM1 and COMT) have been incorporated into pharmacogenetic studies to generate more comprehensive metabolic profiles of
patients. With use of massively parallel sequencing, it is possible to identify additional polymorphisms that fine tune, or redefine,
previous pharmacogenetic findings, which typically rely on targeted approaches. The 1000 Genomes Project data were analyzed to
describe population genetic variation and statistics for these five genes in self-reported healthy individuals in five global super- and
26 sub-populations. Findings on the variation of these genes in various populations expand baseline understanding of
pharmacogenetically relevant polymorphisms for future studies of affected cohorts.
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HIGHLIGHTS
● An in silico genetic analysis of five opiate metabolism genes
(CYP2D6, UGT2B7, ABCB1, OPRM1, and COMT) was performed to
identify SNPs, INDELs, and/or copy number variants in general
populations.
● Allele frequencies, observed and expected heterozygosities, test
results for Hardy Weinberg Equilibrium, and pairwise linkage
disequilibria for polymorphisms in the introns, exons, 3' and 5'
untranslated regions, and promoter regions of five genes are
reported for 2 504 unrelated healthy individuals from five super-
populations and 26 sub-populations.
● Multidimensional scaling plots show substantial inter-super-
population separation while sub-populations show variable
degrees of clustering within super-populations.
● CYP2D6 * alleles were used to determine activity scores for each
sample, potentially identifying poor, intermediate, extensive,
and ultrarapid metabolizer phenotypes in a cohort of self-
reported healthy individuals.
● Principle component analyses of CYP2D6 extensive metabolizers
indicate intra-metabolizer phenotype variation.
INTRODUCTION
Cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) is
a clinically significant enzyme responsible for ~ 30% of phase I
metabolism of ~ 25% of marketed drugs.1,2 Of particular interest is
the enzyme’s role in the conversion of pain medications to active
metabolites, namely morphine.3–5 The highly polymorphic nature
of CYP2D6 results in various metabolizer phenotypes (MP; poor
(PM), intermediate (IM), extensive (EM) and ultra-rapid (UM)),6–8
typically inferred from the diplotype of CYP2D6 star (*) alleles (a
haplotype of one or more polymorphisms along the length of the
gene),9 that have been associated with lack of therapeutic
response, idiosyncratic responses, or even death.10–12
Comprehensive pharmacogenetic studies have shown that
single-nucleotide polymorphisms (SNPs) in other opiate
metabolism and pain relief pathway genes also confer variable
degrees of enzyme activity.13–17 These additional genes of interest
include uridine diphosphate glucuronosyltransferase, family 1,
polypeptide B7 (UGT2B7), adenosine triphosphate-binding
cassette, subfamily B, number 1 (ABCB1), opioid receptor mu 1
(OPRM1) and catechol-O-methyltransferase (COMT). UGT2B7
encodes an enzyme that converts morphine to morphine-6-
glucuronide; these two compounds are the primary cause of the
analgesic effect of opiates. ABCB1 encodes p-glycoprotein
(or multidrug resistance protein 1), a membrane-associated
transporter responsible for the efflux of morphine from various
organs. OPRM1 encodes the primary receptor for signal transduc-
tion of the analgesic response. Finally, COMT encodes a protein
that interacts with the opioid receptor mechanism to modulate
pain response through catecholamine breakdown. Polymorphisms
within these genes can impact opiate metabolism by altering the
performance of their protein products, leading to non-effective
treatment or clinical complications following opiate medication
administration.14,15
Previous pharmacogenetic studies have focused on identifying
common causal polymorphisms using genome-wide association
studies (targeted SNP arrays and targeted massively parallel
sequencing) to determine the MP of ante- and post-mortem
patients.17–19 While valuable, these methods fail to assess
polymorphisms comprehensively in a target sequence on the
individual and population levels. In addition, they hinder discovery
of novel polymorphisms that may provide greater insight into
phenotypic variability and subsequent resequencing of target loci
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may be required for confirmation of allele calls.20 Massively
parallel sequencing of the full gene region may reveal additional
variants, with reliable depth of coverage, which refine the current
working knowledge of CYP2D6 * alleles, for example, those which
introduce premature stop codons before the defining polymorph-
isms of a * allele.
Pharmacogenetic population studies often control for presence
of disease phenotype while placing less emphasis on demography
and population substructure as contributing factors to variable
allele distribution which may confer different metabolic profiles in
populations.10,21,22 Consequently, false positive associations may
arise regarding the relationship between genotype and MP.23
Herein, an in silico study of the complete gene sequences of
CYP2D6, UGT2B7, ABCB1, OPRM1, COMT and their respective
promoter regions was performed to identify novel SNPs, inser-
tion/deletion (INDEL) polymorphisms and copy number variants
(CNVs), define baseline population genetic variation, and identify
potential phenotypic variability in opiate metabolism and pain
relief. A summary is provided of population statistics, variant effect
predictions, and clustering of super- and sub-populations based
on SNPs, INDELs and CNVs in five genes whose protein products
are associated with opiate metabolism. Finally, the distribution of
CYP2D6 * alleles in five super-populations and 26 sub-populations
is shown which provides additional information regarding
variability within the population of EMs.24 These findings serve
as substantial population genetic data for healthy cohorts which
may guide the pharmacogenetics community towards studies
involving comprehensive genetic screening.
MATERIALS AND METHODS
Gene and promoter regions were identified using GeneCards Human Gene
Database.25 Genotype data were obtained from 2504 unrelated healthy
individuals whose sequence data were downloaded from Phase 3 of the
1000 Genomes Project using the University of California Santa Cruz (UCSC)
Table Browser26,27 and the appropriate hg19 reference genome coordi-
nates for CYP2D6, UGT2B7, ABCB1, OPRM1, COMT and their respective
promoter regions. The 1000 Genomes Project reports data with sequence
depth of coverage ≥ 4 × .
Population genetic summary statistics and statistical tests were
performed for five super-populations (African (AFR), Ad Mixed American
(AMR), East Asian (EAS), European (EUR) and South Asian (SAS)) and 26 sub-
population (Supplementary Table 1). Allele frequencies, observed and
expected heterozygosity calculations, and tests for departures from Hardy–
Weinberg equilibrium (HWE) and pairwise linkage disequilibrium
(LD, assuming HWE) were performed using Genetic Data Analysis
Software.28 Allele frequency 95% confidence intervals were estimated
using the normal approximation to the binomial method. Tests for HWE
departures and pairwise LD were performed for super- and sub-popula-
tions due to the potential for loci meeting HWE expectations or pairwise
loci linkage equilibrium in sub-populations but deviating from these
expectations when pooled into super-populations.29 Due to the size of
ABCB1 and OPRM1 and the number of polymorphisms within each gene,
computation constraints with software memory were experienced while
performing all tests for pairwise LD between these polymorphisms (~17
million and ~23 million pairwise comparisons for ABCB1 and OPRM1,
respectively). Consequently, tests for pairwise LD for ABCB1 and OPRM1
polymorphisms were performed between HWE-deviating loci and all other
loci. Both tests are sensitive to low frequency alleles and focusing on this
subset of loci for pairwise LD testing, under the assumption of HWE, could
indicate if the polymorphisms are subject to some selective pressures and/
or genotyping errors as a result of the relatively low coverage of 1000
Genomes Project data.30 Here we use 'linkage disequilibrium block' to
describe a cluster of polymorphisms with significant deviations from
pairwise LD with all other polymorphisms for a gene. Ensembl Variant
Predictor (Release 84, March 2016)31 and Sort Intolerant From Tolerant
(SIFT)32–36 were used to determine SIFT, Polymorphism Phenotyping v2
(PolyPhen-2),37,38 and Protein Variant Effect Analyzer (PROVEAN)39–41
variant effect predictions and scores for all identified polymorphisms.
Intronic positions within 1000 bases of an exon were further analyzed
using Human Splicing Finder (HSF).42 Multidimensional scaling (MDS) plots
and principal component analysis plots were generated in RStudio.43
CYP2D6 * alleles were assigned according to the presence of causal
polymorphisms associated with known phenotype9 and were used to
assign activity scores and MP to each individual.44 Haplotypes producing
no amino acid changes and lacking causal intronic polymorphisms were
considered *1; haplotypes conferring the combination of R296C and S486T
amino acid changes but lacking any other amino acid change and intronic
causal polymorphisms were considered *2. Individuals possessing
CYP2D6 * alleles with undetermined effects on activity (*22, *28 and *43,
for example), or haplotypes that could not be associated with a * allele,
were removed from MP analyses.
RESULTS
CYP2D6
Allele frequencies for 418 polymorphic loci (402 SNPs, 15 INDELs
and one CNV) in the CYP2D6 region for five super-populations
and 26 sub-populations are listed in Supplementary Table 2.
The average observed heterozygosity for 26 sub-populations
was 0.0341±0.102 with a range of 0.0253±0.0836 (CHS) to
0.0439± 0.114 (GWD; Table 1 and Supplementary Table 3). When
pooled, the average super-population observed heterozygosity was
0.0384± 0.0980 for AFR, 0.0337±0.102 for AMR, 0.0281±0.0918 for
EAS, 0.0359±0.107 for EUR and 0.0339±0.107 for SAS (Table 1 and
Supplementary Table 3). After Bonferroni correction (Po0.000120),
one locus in GBR (rs35742686), one locus in EAS (rs374153932) and
four loci in AFR (rs78854695, rs28371705, rs28371703 and
rs376217512) significantly deviated from HWE, all of which are less
than that due to chance alone (that is, ~ 21; Table 2 and
Supplementary Table 4).
After Bonferroni correction, sub-populations exhibited an
average of 470 ± 90 significant pairwise LDs with a range of 331
(ASW) to 721 (KHV) significant pairwise LDs and 3693 AFR, 799
AMR, 1048 EAS, 1031 EUR and 933 SAS significant pairwise LDs
were observed (Po5.74 × 10–7), all of which are less than that due
to chance alone (~4358 pairwise comparisons; Table 2 and
Supplementary Figure 1). LD heat-maps of five super-populations
(Supplementary Figure 2) show a cluster of six to seven
polymorphisms (rs29001678 (AMR, EUR, SAS only), rs1081000,
rs28695233, rs75276289, rs76312385, rs74644586 and rs1080996),
which appear to form an LD block. There were an average of
44 ± 14 significant pairwise LDs between these seven polymorph-
isms and others within the gene, with a range of 33 (AMR) to 71
(AFR) significant pairwise LDs. This group of polymorphisms is
found within CYP2D6 intron 1 (hg19 positions 42526524–
42526573) and do not alter CYP2D6 function; however,
rs1080995, rs74644586 and rs76312385 are part of the
CYP2D6*21A haplotype and may be observed in any CYP2D6 *
allele with an intron 1 gene conversion with CYP2D7 (CYP2D6*11,
*14B, *21B, *63, *73, *84, *88, *98, *102, *103, *104 and *105).9
MDS plots (Figure 1) were created using CYP2D6 polymorphism
pairwise genetic distances between super-populations and within
super-populations (between sub-populations). There was sub-
stantial separation of the AFR and EAS populations from the
cluster of AMR, EUR and SAS populations while sub-population
clustering is quite diverse within each super-population.
Variant effect prediction for 418 CYP2D6 polymorphisms was
performed using SIFT, PolyPhen-2 and PROVEAN (Table 3 and
Supplementary Table 5).32–41 Individual polymorphisms were
assigned to one of five categories based on their SIFT, PolyPhen-2
and PROVEAN scores: tolerated with no discrepancies (predictions
are concordant), discrepancies but most likely tolerated (predictions
are discordant but favor tolerance), discrepancies but most likely
damaging (predictions are discordant but favor intolerance),
damaging with no discrepancies (predictions are concordant) and
conflicting results (only two scores are reported and their
predictions are discordant). Summaries of their frequencies and
distribution across each gene are shown in Table 3 and Figure 2a,
respectively. Due to the potential for multiple alternate alleles at the
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Table 1. Average super-population and sub-population observed (Ho) and expected (He) heterozygosities across 418 CYP2D6, 613 UGT2B7, 5986
ABCB1, 6831 OPRM1 and 1007 COMT polymorphisms.
Gene Super-population Average He Average Ho Sub-population Average He Average Ho
CYP2D6 AFR 0.0429± 0.110 0.0384± 0.0980 YRI 0.0417± 0.110 0.0365± 0.0956
LWK 0.0435± 0.110 0.0386± 0.0984
GWD 0.0433± 0.111 0.0440± 0.114
MSL 0.0420± 0.109 0.0370± 0.0949
ESN 0.0424± 0.111 0.0404± 0.107
ASW 0.0417± 0.108 0.0360± 0.0956
ACB 0.0429± 0.112 0.0346± 0.0895
AMR 0.0372± 0.114 0.0337± 0.102 MXL 0.0340± 0.105 0.0296± 0.0892
PUR 0.0405± 0.120 0.0413± 0.127
CLM 0.0386± 0.115 0.0317± 0.0922
PEL 0.0324± 0.108 0.0296± 0.0983
EAS 0.0308± 0.102 0.0281± 0.0918 CHB 0.0310± 0.101 0.0310± 0.100
JPT 0.0329± 0.109 0.0298± 0.0995
CHS 0.0296± 0.0980 0.0253± 0.0836
CDX 0.0288± 0.0955 0.0260± 0.0843
KHV 0.0275± 0.0910 0.0282± 0.0955
EUR 0.0400± 0.121 0.0359± 0.107 CEU 0.0410± 0.122 0.0353± 0.104
TSI 0.04070± 0.123 0.0373± 0.112
FIN 0.0376± 0.1160 0.0357± 0.111
GBR 0.0402± 0.121 0.0320± 0.0949
IBS 0.0401± 0.121 0.0386± 0.117
SAS 0.0374± 0.118 0.0339± 0.107 GIH 0.0381± 0.121 0.0362± 0.115
PJL 0.0340± 0.111 0.0333± 0.108
BEB 0.0371± 0.1130 0.0312± 0.0949
STU 0.0374± 0.119 0.0309± 0.0975
ITU 0.0381± 0.121 0.0374± 0.119
UGT2B7 AFR 0.0573± 0.117 0.0582± 0.121 YRI 0.0530± 0.109 0.0554± 0.115
LWK 0.0610± 0.125 0.0668± 0.140
GWD 0.0524± 0.110 0.0503± 0.109
MSL 0.0495± 0.103 0.0492± 0.105
ESN 0.0604± 0.124 0.0663± 0.140
ASW 0.0605± 0.125 0.0681± 0.143
ACB 0.0639± 0.134 0.0551± 0.115
AMR 0.0675± 0.150 0.0613± 0.136 MXL 0.0621± 0.140 0.0694± 0.158
PUR 0.0723± 0.161 0.0684± 0.151
CLM 0.0741± 0.166 0.0653± 0.146
PEL 0.0448± 0.105 0.0420± 0.104
EAS 0.0611± 0.142 0.0644± 0.151 CHB 0.0646± 0.150 0.0847± 0.200
JPT 0.0636± 0.145 0.0654± 0.149
CHS 0.0605± 0.141 0.0698± 0.165
CDX 0.0595± 0.139 0.0468± 0.111
KHV 0.0570± 0.133 0.0529± 0.127
EUR 0.0741± 0.168 0.0777± 0.177 CEU 0.0738± 0.169 0.0836± 0.193
TSI 0.0745± 0.167 0.0834± 0.189
FIN 0.0744± 0.168 0.0665± 0.150
GBR 0.0726± 0.167 0.0725± 0.168
IBS 0.0746± 0.168 0.0814± 0.184
SAS 0.0720± 0.164 0.0740± 0.170 GIH 0.0727± 0.167 0.0744± 0.172
PJL 0.0738± 0.165 0.0730± 0.165
BEB 0.0701± 0.159 0.0731± 0.167
STU 0.0719± 0.165 0.0780± 0.181
ITU 0.0713± 0.164 0.0713± 0.166
ABCB1 AFR 0.0295± 0.0872 0.0294± 0.0873 YRI 0.0288± 0.0884 0.0287± 0.0885
LWK 0.0309± 0.0909 0.0300± 0.0880
GWD 0.0283± 0.0860 0.0296± 0.0914
MSL 0.0303± 0.0875 0.0295± 0.0855
ESN 0.0302± 0.0895 0.0300± 0.0903
ASW 0.0279± 0.0847 0.0277± 0.0853
ACB 0.0294± 0.0877 0.0297± 0.0893
AMR 0.0209± 0.0771 0.0209± 0.0781 MXL 0.0202± 0.0783 0.0194± 0.0775
PUR 0.0209± 0.0763 0.0219± 0.0812
CLM 0.0215± 0.0779 0.0212± 0.0767
PEL 0.0199± 0.0780 0.0205± 0.0821
EAS 0.0186± 0.0758 0.0184± 0.0751 CHB 0.0177± 0.0733 0.0171± 0.0711
JPT 0.0193± 0.0775 0.0196± 0.0795
CHS 0.0192± 0.0779 0.0191± 0.0762
CDX 0.0177± 0.0747 0.0182± 0.0789
KHV 0.0188± 0.0769 0.0178± 0.0735
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Table 1. (Continued )
Gene Super-population Average He Average Ho Sub-population Average He Average Ho
EUR 0.0189± 0.0759 0.0192± 0.0780 CEU 0.0185± 0.0757 0.0193± 0.0807
TSI 0.0195± 0.0771 0.0186± 0.0738
FIN 0.0184± 0.0753 0.0188± 0.0785
GBR 0.0182± 0.0762 0.0191± 0.0801
IBS 0.0193± 0.0778 0.0201± 0.0817
SAS 0.0174± 0.0688 0.0173± 0.0678 GIH 0.0175± 0.0706 0.0169± 0.0666
PJL 0.0185± 0.0724 0.0185± 0.0723
BEB 0.0170± 0.0677 0.0175± 0.0695
STU 0.0165± 0.0658 0.0159± 0.0631
ITU 0.0175± 0.0707 0.0174± 0.0713
OPRM1 AFR 0.0405± 0.101 0.0407± 0.102 YRI 0.0408± 0.104 0.0413± 0.106
LWK 0.0412± 0.104 0.04100± 0.102
GWD 0.0392± 0.101 0.0399± 0.105
MSL 0.0380± 0.0968 0.0384± 0.0983
ESN 0.0430± 0.108 0.0425± 0.107
ASW 0.0390± 0.100 0.0414± 0.109
ACB 0.0396± 0.100 0.0404± 0.103
AMR 0.0299± 0.0949 0.0291± 0.0923 MXL 0.0302± 0.0982 0.0327± 0.108
PUR 0.0313± 0.0953 0.0307± 0.0945
CLM 0.0304± 0.0954 0.0309± 0.0983
PEL 0.0244± 0.0852 0.0225± 0.0778
EAS 0.0225± 0.0822 0.0228± 0.0835 CHB 0.0232± 0.083 0.0235± 0.0844
JPT 0.0206± 0.0810 0.0210± 0.0824
CHS 0.0235± 0.0834 0.0241± 0.0858
CDX 0.0223± 0.0835 0.0228± 0.0873
KHV 0.0226± 0.0829 0.0226± 0.0830
EUR 0.0299± 0.0962 0.0302± 0.0980 CEU 0.0304± 0.0984 0.0302± 0.0987
TSI 0.0290± 0.0939 0.0293± 0.0977
FIN 0.0299± 0.0967 0.0315± 0.103
GBR 0.0297± 0.0960 0.0292± 0.0957
IBS 0.0304± 0.0981 0.0309± 0.0994
SAS 0.0259± 0.0881 0.0258± 0.0888 GIH 0.0266± 0.0897 0.0265± 0.0901
PJL 0.0256± 0.0880 0.0264± 0.0924
BEB 0.0250± 0.0860 0.0245± 0.0851
STU 0.0263± 0.0897 0.0267± 0.0916
ITU 0.0254± 0.0887 0.0248± 0.0883
COMT AFR 0.0489± 0.118 0.049± 0.118 YRI 0.0479± 0.118 0.0467± 0.114
LWK 0.0493± 0.118 0.0479± 0.114
GWD 0.0498± 0.121 0.0520± 0.128
MSL 0.0484± 0.117 0.0473± 0.114
ESN 0.0474± 0.117 0.0514± 0.131
ASW 0.0503± 0.120 0.0498± 0.120
ACB 0.0493± 0.120 0.0481± 0.117
AMR 0.0453± 0.123 0.0442± 0.121 MXL 0.0442± 0.121 0.0462± 0.128
PUR 0.0466± 0.125 0.0445± 0.120
CLM 0.0461± 0.124 0.0472± 0.127
PEL 0.0372± 0.111 0.0392± 0.123
EAS 0.0429± 0.124 0.0425± 0.122 CHB 0.0442± 0.125 0.0423± 0.120
JPT 0.0442± 0.124 0.0466± 0.131
CHS 0.0411± 0.123 0.0420± 0.126
CDX 0.0423± 0.123 0.0392± 0.115
KHV 0.0424± 0.124 0.0418± 0.123
EUR 0.0435± 0.122 0.0443± 0.125 CEU 0.0435± 0.123 0.0458± 0.130
TSI 0.0441± 0.125 0.0467± 0.133
FIN 0.0414± 0.115 0.0401± 0.112
GBR 0.0437± 0.124 0.0436± 0.124
IBS 0.0428± 0.122 0.0451± 0.129
SAS 0.0456± 0.123 0.0437± 0.118 GIH 0.0463± 0.125 0.0460± 0.124
PJL 0.0455± 0.124 0.0446± 0.123
BEB 0.0448± 0.123 0.0404± 0.111
STU 0.0459± 0.124 0.0417± 0.112
ITU 0.0444± 0.121 0.0452± 0.126
Abbreviations: AFR, African; AMR, Ad Mixed American; ACB, African Caribbean in Barbados; ASW, American of African Ancestry in Southwest USA; BEB, Bengali
from Bangladesh; CDX, Chinese Dai in Xishuangbanna, China; CEU, Utah Residence with Northern and Western Ancestry; CHB, Han Chinese in Beijing; CHS,
Southern Han Chinese; CLM, Colombians from Medellin, Colombia; EAS, East Asian; ESN, Esan in Nigeria; EUR, European; FIN, Finnish in Finland; GBR, British in
England and Scotland; GIH, Gujarati Indian from Houston, Texas; GWD, Gambian in Western Divisions in Gambia; IBS, Iberian Population in Spain; ITU, Indian
Telugu from the United Kingdom; JPT, Japanese in Tokyo, Japan; KHV, Kinh in Ho Chi Minh City, Vietnam; LWK, Luhya in Webuye, Kenya; MSL, Mende in Sierra
Leone; MXL, Mexican Ancestry from Los Angeles, USA; PEL, Peruvians from Lima, Peru; PJL, Punjabi from Lahore, Pakistan; PUR, Puerto Ricans from Puerto Rico;
SAS, South Asian; STU, Sri Lankan Tamil from the United Kingdom; TSI, Toscani in Italia; YRI, Yoruba in Ibadan, Nigeria.
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Table 2. Number of loci that deviated from HWE expectations and the number of pairwise loci comparisons that exhibited LD for CYP2D6, UGT2B7,
ABCB1, OPRM1 and COMT polymorphisms in five super-populations and 26 sub-populations. Bonferroni corrected HWE P-values were 0.000120,
8.16 × 10− 5, 8.35 X 10− 6, 7.32 × 10− 6 and 4.96 × 10− 5 for CYP2D6, UGT2B7, ABCB1, OPRM1 and COMT, respectively; Bonferroni corrected pairwise LD
P-values were 5.34 × 10− 7, 2.67 × 10− 7, 5.50 × 10− 8, 2.24 × 10− 8 and 9.87 × 10− 8 for CYP2D6, UGT2B7, ABCB1, OPRM1 and COMT, respectively.
Gene Super-population Significant HWE deviations Significant LDs Sub-population Significant HWE deviations Significant LDs
CYP2D6 AFR 4 3693 YRI 0 516
LWK 0 500
GWD 0 449
MSL 0 452
ESN 0 422
ASW 0 331
ACB 0 634
AMR 0 799 MXL 0 383
PUR 0 560
CLM 0 504
PEL 0 380
EAS 1 1048 CHB 0 438
JPT 0 385
CHS 0 455
CDX 0 425
KHV 0 721
EUR 0 1031 CEU 0 595
TSI 0 494
FIN 0 387
GBR 1 575
IBS 0 402
SAS 0 933 GIH 0 402
PJL 0 443
BEB 0 472
STU 0 512
ITU 0 393
UGT2B7 AFR 4 7728 YRI 2 4403
LWK 0 3643
GWD 2 4271
MSL 1 4053
ESN 2 4711
ASW 0 2671
ACB 0 3546
AMR 3 7282 MXL 0 2917
PUR 0 3526
CLM 0 3731
PEL 1 3160
EAS 2 5308 CHB 36 24 147
JPT 1 3965
CHS 2 4500
CDX 1 4174
KHV 1 4313
EUR 3 6295 CEU 1 4153
TSI 0 3793
FIN 0 4332
GBR 0 3743
IBS 1 4159
SAS 3 6574 GIH 0 3405
PJL 2 3968
BEB 1 3542
STU 1 3962
ITU 3 4959
ABCB1 AFR 9 72 978 YRI 0 11 405
LWK 0 4972
GWD 1 12 227
MSL 2 14 988
ESN 1 12 071
ASW 0 2947
ACB 1 13 847
AMR 2 31 011 MXL 0 7170
PUR 1 9362
CLM 1 11 249
PEL 0 5597
EAS 5 37 802 CHB 2 15 053
JPT 0 5892
CHS 2 15 271
CDX 0 6908
KHV 1 9580
EUR 2 26 637 CEU 2 10 442
TSI 0 9939
FIN 0 3123
GBR 1 8771
IBS 1 9135
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54 damaging, or most likely damaging, polymorphisms (locus
rs1135830, for example, can produce a non-synonymous amino
acid change or a premature stop codon), 47 single-amino acid
changes, 4 premature stop codons, 2 frame-shift mutations, 1 CNV,
1 in-frame insertion and 1 in-frame deletion mutations would arise.
Fifty percent (80/160) of the intronic and/or splice-associated
polymorphisms were scored by HSF (Figure 2a and Supplementary
Table 5). Seven of these loci (rs5030656, rs192358451, rs377504871,
rs78854695, rs267608282, rs28371702 and rs267608275) were
predicted to alter, or most likely alter, splicing of the gene. The
locus rs28371702 is considered part of the haplotype for 35 * alleles
although it has not been reported as functionally relevant.9 The
remaining six polymorphisms have not been reported as part of a
recognized * allele. Interestingly, the four intronic polymorphisms
Table 2. (Continued )
Gene Super-population Significant HWE deviations Significant LDs Sub-population Significant HWE deviations Significant LDs
SAS 3 25 566 GIH 1 8190
PJL 1 9611
BEB 1 8979
STU 1 10 653
ITU 1 9323
OPRM1 AFR 12 172 560 YRI 2 36 581
LWK 1 27 603
GWD 4 47 005
MSL 2 33 978
ESN 0 24 996
ASW 0 11 928
ACB 1 18 034
AMR 5 92 744 MXL 2 30 805
PUR 1 31 564
CLM 2 36 436
PEL 0 60 103
EAS 5 62 824 CHB 2 33 915
JPT 4 38 296
CHS 2 32 577
CDX 2 23 930
KHV 5 42 291
EUR 6 76 181 CEU 3 36 491
TSI 2 32 190
FIN 1 33 169
GBR 4 37 849
IBS 1 22 631
SAS 5 77 803 GIH 1 30 707
PJL 4 41 472
BEB 2 23 612
STU 4 44 452
ITU 3 33 269
COMT AFR 1 7362 YRI 0 1421
LWK 0 1428
GWD 0 1252
MSL 0 1003
ESN 2 2492
ASW 0 772
ACB 0 1132
AMR 2 7004 MXL 0 1196
PUR 0 2068
CLM 2 1669
PEL 0 4661
EAS 2 6712 CHB 0 2396
JPT 0 1940
CHS 0 1777
CDX 0 1890
KHV 1 3079
EUR 3 7835 CEU 1 2229
TSI 0 1685
FIN 2 2123
GBR 0 2162
IBS 0 2391
SAS 2 7502 GIH 0 2202
PJL 0 1870
BEB 0 3969
STU 3 5326
ITU 0 1874
Abbreviations: ACB, African Caribbean in Barbados; AFR, African; AMR, Ad Mixed American; ASW, American of African Ancestry in Southwest USA; BEB, Bengali
from Bangladesh; CDX, Chinese Dai in Xishuangbanna, China; CEU, Utah Residence with Northern and Western Ancestry; CHB, Han Chinese in Beijing;
CHS, Southern Han Chinese; CLM, Colombians from Medellin, Colombia; EAS, East Asian; ESN, Esan in Nigeria; EUR, European; FIN, Finnish in Finland; GBR,
British in England and Scotland; GIH, Gujarati Indian from Houston, Texas; GWD, Gambian in Western Divisions in Gambia; HWE, Hardy–Weinberg Equilibrium;
IBS, Iberian Population in Spain; ITU, Indian Telugu from the United Kingdom; JPT, Japanese in Tokyo, Japan; KHV, Kinh in Ho Chi Minh City, Vietnam; LD,
linkage disequilibrium; LWK, Luhya in Webuye, Kenya; MSL, Mende in Sierra Leone; MXL, Mexican Ancestry from Los Angeles, USA; PEL, Peruvians from Lima,
Peru; PJL, Punjabi from Lahore, Pakistan; PUR, Puerto Ricans from Puerto Rico; SAS, South Asian; STU, Sri Lankan Tamil from the United Kingdom; TSI, Toscani in
Italia; YRI, Yoruba in Ibadan, Nigeria.
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that are recognized by The Human Cytochrome p450 Allele
Nomenclature Database9 for causing splice-defects (883G4C
[rs201377835], 1846G4A [rs3892097], 2950G4C (no rs number;
invariable according to 1000 Genomes Project) and 2988G4A
[rs28371725]) were either not scored by HSF or not considered
variable sites in the 1000 Genomes Project and so genotypes were
not exported from the UCSC Table Browser.
The Human CYP Allele Nomenclature Database9 was used to
assign * alleles to each sample. 210 unique haplotypes were
observed in the 1000 Genomes Project Phase 3 data set,
representing 37 * alleles (Supplementary Table 6). The average
super-population observed and expected heterozygosities were
0.72 ± 0.080 and 0.78 ± 0.091, respectively. Using * allele
assignments, CYP2D6 significantly deviated from HWE expecta-
tions after Bonferroni correction in the AFR, AMR, EAS and SAS
super-populations (Po0.0348 for AFR and P= 0.0420, 0.0442 and
0.0348 in AMR, EAS and SAS, respectively) and seven sub-
populations (P = 0.000200, 0.0277, 0.00290, 0.00510, 0.0202, 0.157
and 0.423 in ASW, LWK, MSL, YRI, CLM, British in England and
Scotland and STU, respectively). After Bonferroni correction
(P= 0.01 and P= 0.0019 for super- and sub-populations,
respectively), the AFR super-population (Po0.01) and ASW
sub-population (P= 0.000200) significantly deviated from HWE
expectations. Of the 210 observed haplotypes, only 14 (6.67%) are
identical to those reported in the Human CYP Allele Nomenclature
Table. Though not reported in the reference table, 84.8% of the
remaining haplotypes could be associated with a * allele
based on the presence of causal polymorphisms, however, 18 of
them could not. These haplotypes represent 0.499% (25/5008) of
the total 1000 Genomes Project haplotypes and contain
Figure 1. Multidimensional scaling plots of CYP2D6 polymorphism pairwise genetic distances of five super-populations and 26
sub-populations based on 1000 Genome Project Phase 3 genotype data. African (AFR) populations are marked with a blue diamond, Ad
Mixed American (AMR) populations are marked with a green plus sign, East Asian (EAS) populations are marked with a red 'X', European (EUR)
populations are marked with a purple minus sign and South Asian (SAS) populations are marked with a solid black circle.
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Table 3. Polymorphism effect categories for CYP2D6, UGT2B7, ABCB1, OPRM1 and COMT and promoter regions. Note that not all polymorphisms were assigned a score by each variant effect
algorithm so the total counts for each algorithm may not equal the total of the other algorithms and may be different than the total number of polymorphisms for each gene (N).
Algorithm Effect category CYP2D6 (N= 119) UGT2B7 (N= 55) ABCB1 (N= 94) OPRM1 (N= 75) COMT (N= 45)
Count Average score Count Average score Count Average score Count Average score Count Average score
SIFT Damaging 3 0.00900± 0.00870 0 – 0 – 10 0.000400± 0.00130 4 0.0165± 0.0158
Deleterious 47 0.0157± 0.0147 17 0.0124± 0.0182 30 0.0160± 0.0167 6 0.00670± 0.103 3 0.00330± 0.00580
Tolerated 63 0.634± 0.3707 33 0.666± 0.397 38 0.286± 0.239 46 0.324± 0.384 38 0.616± 0.364
PolyPhen-2 Probably damaging 16 0.978± 0.0241 5 0.963± 0.0322 5 0.9688± 0.0377 16 0.991± 0.0209 0 –
Possibly damaging 17 0.743± 0.147 7 0.726± 0.0986 16 0.692± 0.117 5 0.682± 0.196 4 0.718± 0.194
Benign 43 0.116± 0.129 22 0.0493± 0.0833 47 0.0505± 0.0714 21 0.0636± 0.0917 11 0.0939± 0.133
PROVEAN Deleterious 52 − 4.89± 2.16 18 − 5.05± 2.41 30 − 4.90± 2.23 19 − 4.54± 1.56 5 − 5.20± 1.94
Neutral 61 − 0.422± 0.978 37 − 0.204± 0.839 64 − 0.708± 0.851 56 − 0.0130± 0.518 40 − 0.186± 0.531
Polymorphism effect Count Frequency (%) Count Frequency (%) Count Frequency (%) Count Frequency (%) Count Frequency (%)
Damaging, no discrepancies 36 30.3 12 21.8 12 12.8 0 0 4 8.89
Discrepancies, most likely damaging 18 15.1 3 5.45 13 13.8 17 22.7 1 2.22
Discrepancies, most likely tolerated 10 8.40 5 9.09 19 20.2 13 17.3 1 2.22
Tolerated, no discrepancies 53 44.5 35 63.6 50 53.2 36 48.0 36 80.0
Conflicting results 2 1.68 0 0 0 0 9 12.0 3 6.67
Algorithm Effect category CYP2D6 (N= 80) UGT2B7 (N= 104) ABCB1 (N=564) OPRM1 (N= 126) COMT (N=84)
Count Average score Count Average score Count Average score Count Average score Count Average score
HSF Alters 43 74.8± 6.15 62 74.2± 7.39 293 72.6± 9.14 64 70.7± 12.9 49 70.6± 14.0
74.8± 6.16 74.4± 8.56 70.9± 9.08 70.3± 11.6 74.4± 9.51
− 0.165± 6.13 1.50± 14.3 3.92± 26.6 6.16± 51.8 11.7± 36.3
44.3± 10.4 47.7± 7.14 50.1± 15.5 52.3± 15.5 50.6± 12.1
Creates 27 74.2± 6.88 22 73.3± 6.69 85 72.3± 7.80 40 70.8± 9.02 23 75.7± 7.89
71.7± 79.8 55.6 ± 16.8 73.0± 118 49.9± 68.1 57.1± 42.3
Breaks 73.5± 7.38 72.6± 9.44 72.3± 9.28 72.1± 10.1 74.9± 4.93
29 43.8± 13.2 24 53.4± 13.1 151 51.8± 16.0 34 53.7± 16.8 16 48.6± 11.8
– 26.8± 15.7 24.4± 27.1 25.7± 30.7 23.2± 32.4 34.8± 16.2
Activates cryptic site 35.2± 18.5 46.7± 0.445 51.6± 18.4 45.7± 6.29 44.2± 2.53
3 75.2± 7.88 2 74.6± 1.05 126 72.8± 8.14 3 69.4± 3.15 3 71.0± 2.53
182± 164 59.8± 3.77 79.58± 145.7 54.2± 22.2 60.85± 3.46
Polymorphism effect Count Frequency (%) Count Frequency (%) Count Frequency (%) Count Frequency (%) Count Frequency (%)
Most likely effects splicing 4 5.00 2 1.92 127 22.5 3 2.38 3 3.57
Potentially effects splicing 3 3.75 9 8.65 171 30.3 13 10.3 8 9.52
Probably no effect on splicing 73 91.25 93 89.4 266 47.2 110 87.3 73 86.9
Abbreviations: HSF, Human Splicing Finder. SIFT, PolyPhen-2 and PROVEAN score cutoffs are 0.05, 0.5 and −2.5, respectively, for distinguishing between harmful and tolerated polymorphisms.26–35 SIFT
'damaging' and 'deleterious' predictions, and PolyPhen-2 'probably damaging' and 'possibly damaging' predictions, are qualitative classifications indicating greater and lesser degrees of confidence, respectively,
in the predicted damage caused by a polymorphism.26–32 Average HSF scores are reference (hg19) consensus score, mutant consensus score and variation score.42
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Figure 2. Qualitative summary of variant effect predictions. Each grey box represents a single gene: CYP2D6 (a), UGT2B7 (b), ABCB1 (c), OPRM1
(d) and COMT (e); the top vertical bars of each gene represent exonic polymorphisms scored by Sort Intolerant From Tolerant (SIFT), PolyPhen-
2 and/or PROVEAN, the bottom bars represent intronic and splice-associated polymorphisms within 1000 bases of an exon that were scored
by Human Splicing Finder (HSF), and black lines spanning both sections represent large unscored intronic regions that were removed; CYP2D6
(a) and UGT2B7 (b) are to scale while ABCB1 (c), OPRM1 (d) and COMT (e) have large intronic sequences (vertical black lines) removed; hg19
reference genome coordinates are provided.
Global opiate metabolism genetic variation
FR Wendt et al
289
© 2018 Macmillan Publishers Limited, part of Springer Nature. The Pharmacogenomics Journal (2018), 281 – 294
combinations of functionally relevant amino acid changes
(Supplementary Table 6).
MP was assigned according to Gaedigk et al.44 (Table 4). A χ2
goodness-of-fit test indicated no significant differences between
observed MP frequencies of 1000 Genomes Project super-
population data and theoretical predictions (P= 0.99), previously
reported values for general United States major population groups
(P= 0.54),45 and world populations (African, American, East Asian,
European and South Central Asian; P= 0.99).24
EM individuals were used to create principal component
analysis plots by population (Figure 3). By super-population, the
EM individuals display six prominent clusters with minimal overlap
between AFR and EAS super-populations and considerable spread
of the AMR, EUR and SAS populations across the entire plot. PC1
and PC2 explain greater than 5% of the variance for 10 and 8
polymorphisms, respectively. The same clustering pattern is
observed for sub-populations with little clustering observed
within populations (data not shown).
UGT2B7, ABCB1, OPRM1 and COMT
Allele frequencies for 613 UGT2B7 polymorphisms (585 SNPs and
28 INDELs), 5986 ABCB1 polymorphisms (5775 SNPs, 210 INDELs
and one CNV), 6831 OPRM1 polymorphisms (6561 SNPs, 267
INDELs, 2 ALU element insertions and 1 CNV) and 1007 COMT
polymorphisms (973 SNPs, 33 INDELs and one CNV) in 5 super-
populations and 26 sub-populations are listed in Supplementary
Tables 7–10.
The average super-population and sub-population observed
and expected heterozygosities are listed in Table 1. A full list of
each polymorphism and respective population-specific observed
and expected heterozygosities are shown in Supplementary
Tables 11–14.
A summary of the total number of polymorphisms in each gene
and population that deviated from HWE expectations is listed in
Table 2. A comprehensive list of HWE p-values for each poly-
morphism in each population is provided in Supplementary Tables
15–18. After Bonferroni correction, UGT2B7 loci rs541550034 and
rs57075995 (Po8.16 × 10–5), ABCB1 loci rs546527793 and rs570
071012 (Po8.35 × 10–6), and OPRM1 loci rs147765820,
rs376391508, rs77321666 and rs111829729 (Po7.32 × 10–6)
deviated from HWE expectations in all five super-populations.
While no COMT loci deviated from HWE expectations in the five
super-populations (P= 4.97 × 10–5), it should be noted that the loci
rs138433986 and rs11912354 did deviate from HWE expectations
Table 4. CYP2D6 metabolizer status counts and frequencies in 5 super-populations (bold) and 26 sub-populations based on available 1000 Genomes
Phase 3 causative SNP genotype data. The number of individuals in each population is indicated in parentheses; 'Undetermined' metabolizer
phenotype individuals contain at least one CYP2D6* allele with unknown effect on enzyme activity.
Population Poor Intermediate Extensive Ultrarapid Undetermined
Count Frequency Count Frequency Count Frequency Count Frequency Count Frequency
AFR (661) 9 0.0136 35 0.0530 564 0.853 0 0 53 0.0802
ACB (96) 2 0.0208 6 0.0625 82 0.8542 0 0 6 0.0625
GWD (113) 1 0.00885 2 0.0177 103 0.912 0 0 7 0.0619
ESN (99) 1 0.0101 11 0.111 79 0.798 0 0 8 0.0808
MSL (85) 3 0.0353 2 0.0235 70 0.824 0 0 10 0.118
YRI (108) 0 0 5 0.0463 97 0.898 0 0 6 0.0556
LWK (99) 0 0 4 0.0404 84 0.848 0 0 11 0.111
ASW (61) 2 0.0328 5 0.0820 49 0.803 0 0 5 0.0820
AMR (347) 10 0.0288 10 0.0288 291 0.839 0 0 36 0.104
PUR (104) 6 0.0577 5 0.0481 81 0.779 0 0 12 0.115
CLM (94) 4 0.0426 4 0.0426 74 0.787 0 0 12 0.128
PEL (85) 0 0 0 0 78 0.918 0 0 7 0.0824
MXL (64) 0 0 1 0.0156 58 0.906 0 0 5 0.0781
EAS (504) 0 0 13 0.0258 488 0.968 0 0 3 0.00595
CHS (105) 0 0 3 0.0286 100 0.952 0 0 2 0.0190
CDX (93) 0 0 3 0.0323 89 0.957 0 0 1 0.0108
KHV (99) 0 0 5 0.0505 94 0.949 0 0 0 0
CHB (103) 0 0 2 0.0194 101 0.981 0 0 0 0
JPT (104) 0 0 0 0 104 1 0 0 0 0
EUR (503) 29 0.0577 32 0.0636 433 0.861 0 0 9 0.0179
CEU (99) 5 0.0505 9 0.0909 81 0.818 0 0 1 0.0101
GBR (91) 11 0.121 11 0.121 68 0.747 0 0 1 0.0110
IBS (107) 3 0.0280 2 0.0187 98 0.916 0 0 4 0.0374
TSI (107) 5 0.0467 7 0.0654 93 0.869 0 0 2 0.0187
FIN (99) 5 0.0505 3 0.0303 90 0.909 0 0 1 0.0101
SAS (489) 10 0.0204 24 0.0491 441 0.902 2 0.00409 12 0.0245
PJL (96) 1 0.0104 7 0.0729 87 0.906 0 0 1 0.0104
BEB (86) 2 0.0233 5 0.0581 76 0.884 0 0 3 0.0349
STU (102) 3 0.0294 4 0.0392 90 0.882 1 0.00980 4 0.0392
ITU (102) 3 0.0294 5 0.0490 90 0.882 1 0.00980 3 0.0294
GIH (103) 1 0.00971 3 0.0291 98 0.951 0 0 1 0.00971
Abbreviations: AFR, African; AMR, Ad Mixed American; ACB, African Caribbean in Barbados; ASW, American of African Ancestry in Southwest USA; BEB, Bengali
from Bangladesh; CDX, Chinese Dai in Xishuangbanna, China; CEU, Utah Residence with Northern and Western Ancestry; CHB, Han Chinese in Beijing; CHS,
Southern Han Chinese; CLM, Colombians from Medellin, Colombia; EAS, East Asian; EUR, European; ESN, Esan in Nigeria; FIN, Finnish in Finland; GBR, British in
England and Scotland; GIH, Gujarati Indian from Houston, Texas; GWD, Gambian in Western Divisions in Gambia; IBS, Iberian Population in Spain; ITU, Indian
Telugu from the United Kingdom; JPT, Japanese in Tokyo, Japan; KHV, Kinh in Ho Chi Minh City, Vietnam; LWK, Luhya in Webuye, Kenya; MSL, Mende in Sierra
Leone; MXL, Mexican Ancestry from Los Angeles, USA; PEL, Peruvians from Lima, Peru; PJL, Punjabi from Lahore, Pakistan; PUR, Puerto Ricans from Puerto Rico;
SAS, South Asian; STU, Sri Lankan Tamil from the United Kingdom; TSI, Toscani in Italia; YRI, Yoruba in Ibadan, Nigeria.
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in the AMR, EAS, EUR and SAS populations (P= 0.0009 and 0.0009).
One sub-population, CHB, exhibited more deviations from HWE
expectations than that due to chance alone (that is, ~ 20).
A summary of the total number of pairwise loci comparisons
that demonstrated significant LDs are listed in Table 2 and the
distribution of LD P-values is shown in Supplementary Figures 3–6.
After Bonferroni correction, sub-populations exhibited an average
of 4683 ± 4004, 9489 ± 3368, 33 303± 9716 and 2154 ± 1071
significant LDs for UGT2B7, ABCB1, OPRM1 and COMT, respectively.
Pairwise LD heat-maps of UGT2B7, ABCB1, OPRM1 and COMT
polymorphisms in five major super-populations (Supplementary
Figures 7–10) show no substantial linkage blocks.
In contrast to CYP2D6, the individual MDS plots for UGT2B7,
ABCB1, OPRM1 and COMT show substantial separation for all
super-populations (Figure 4). Within super-populations, sub-
populations cluster relatively well with minimal overlap between
super-populations. Considering the entire data set of ~ 15 000
polymorphisms, MDS plots of super-populations follow the
pattern observed with single-gene plots. However, sub-popul-
ations do not show any clustering within their respective
super-populations.
Variant effect prediction was performed on 613 UGT2B7, 5986
ABCB1, 6831 OPRM1 and 1007 COMT polymorphisms to generate
SIFT, PolyPhen-2 and PROVEAN scores (Supplementary Tables
19–22).32–41 A summary of the average score and frequency of
each variant effect is displayed in Table 3. Of the damaging, or
most likely, damaging, exonic polymorphisms in UGT2B7, ABCB1,
OPRM1 and COMT, 100% (15/15, 25/25, 17/17 and 5/5 polymorph-
isms in UGT2B7, ABCB1, OPRM1 and COMT, respectively) are the
result of single-amino acid changes. Intronic polymorphisms were
analyzed further using HSF (Table 3). Those most likely to alter
splicing of UGT2B7, OPRM1 and COMT account for o5% of the
total number of polymorphisms scored by HSF. The intronic
polymorphisms of ABCB1 predicted to most likely, or potentially,
alter splicing account for over 50% of the total (Table 3). These
polymorphisms are distributed across introns 1 through 16, with
very few splice-altering polymorphisms occurring after intron 16
(Figure 2c). In addition, one COMT polymorphism was recognized
by the variant effect predictors as a frame-shift mutation
(rs563298832) but was not assigned a score by the three
algorithms used. Manual inspection of the locus in IGV shows
the CATT deletion within intron 5 so assignment as a frame-shift
mutation is incorrect. The HSF algorithm did not score this locus
either. It is possible that this intronic polymorphism is damaging
to the resulting protein, however, this assumption is not
supported or refuted by the data presented.
Intergenic linkage disequilibria
A total of 1349 polymorphisms across all five target genes were
assigned SIFT, PolyPhen-2, PROVEAN and/or HSF scores. Tests for
pairwise LD were performed on this subset of loci to address
potential linkage disequilibria between polymorphisms that may
alter the activity of multiple proteins. After Bonferroni correction
(5.50 × 10–8), 9573 AFR, 1328 AMR, 2517 EAS, 3134 EUR and 2583
SAS significant pairwise LDs were observed between polymorphic
loci of different genes (Po0.0004, Supplementary Table 23). The
number of significant pairwise LDs is less than that due to chance
alone (that is, ~ 45 461), however, those that contain two causal
polymorphisms may be clinically significant. After removal of
significant pairwise LDs containing loci which deviate from HWE
expectations, there were 539, 12, 124, 282 and 128 significant
pairwise LDs in the AFR, AMR, EAS, EUR and SAS populations,
respectively, between polymorphic loci in different genes that are
predicted to be damaging, or most likely damaging to the
resulting protein (Figure 5). Two polymorphisms are part of 82.2,
98.4, 46.8 and 85.9% of these significant pairwise LDs within AFR,
EAS, EUR and SAS, respectively (rs5885589 and rs677830).
Rs5885589 is an ABCB1 intronic polymorphism which breaks an
existing splice site and activates a cryptic splice site just upstream
of exon 17. Rs677830 is found within exon 4 of OPRM1 and confers
glutamine411stop in transcript variant 1B5. https://www.ncbi.nlm.
nih.gov/nuccore/NM_001145286.2. The AMR population does not
have a substantial percentage of pairwise LDs associated with a
single polymorphism.
Figure 3. Principal component (PC) analysis of CYP2D6 extensive metabolizers using genotypes of 418 polymorphisms from 1000 Genomes
Project Phase 3. Samples are clustered according to super-population; rs numbers are provided for those loci best explained by PC1 and PC2;
functional relevance of the polymorphism is indicated in reference to The Human Cytochrome p450 Allele Nomenclature Table9 and
concordance with variant effect prediction generated by SIFT, PolyPhen-2, PROVEAN and HSF with green and red cells indicating tolerance
and damage, respectively.
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Figure 4. Multidimensional scaling plots of UGT2B7, ABCB1, OPRM1 and COMT polymorphism pairwise genetic distances of 5 super-populations
and 26 sub-populations based on 1000 Genome Project Phase 3 genotype data. African (AFR) populations are marked with a blue
diamond, Ad Mixed American (AMR) populations are marked with a green plus sign, East Asian (EAS) populations are marked with a
red 'X', European (EUR) populations are marked with a purple minus sign and South Asian (SAS) populations are marked with a solid black
circle.
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DISCUSSION
Our study is limited by two factors. First, the coverage requirement
for the 1000 Genomes Project is ~ 4 × , producing an inherent level
of missing variants or error in the sequence data. Second, due to
limited size in each sub-population, some rare alleles may not be
observed due to sample size. When data are generated in-house
with greater sub-population samples sizes, greater coverage can
be applied that will reduce the level of error and increase the
chance of observing rare alleles. However, our analyses add to the
population studies on pharmacogenetically interesting genes at
global scale.46–48
Potential contributors to the number of significant deviations
from HWE expectations that were observed for CYP2D6 and
UGT2B7 polymorphisms in the ACB and CHB populations,
respectively, are allele drop-out, the effects of selection and/or
population substructure. For both sub-populations, some degree
of substructure has been reported.49–51 The Barbadian (ACB)
population has demonstrated a higher degree of substructure
relative to other ancestral African populations.49,50 The Han
Chinese also show some degree of substructure attributed to
northern and southern Han populations. It has been shown that
the 1000 Genomes CHB population contains individuals from
these Han sub-groups.51
The 1000 Genomes Project contains self-reported healthy
individuals and as such, the prevalence of CYP2D6 PM, IM and
UM metabolizers may not reflect previously published data sets
focusing on cohorts of affected individuals. The principal
component analysis plots of EMs explain relatively little variation
(5.0 and 3.2%, respectively, for principle components one and
two). These data support previous work demonstrating some level
of intra-metabolizer status variability as well as intra-sub-
population variability, which is supported by MDS plot of each
population.
The CYP2D6 MDS plots show separation of AFR and EAS from
the cluster of AMR, EUR and SAS, supporting previously reported
clinical differences between these populations.52 Lack of tight sub-
population (within super-population) clustering supports previous
findings that CYP2D6 activity variation may be greater within than
between super-populations.53 For example, the sub-populations
within the EAS super-population (CDX, CHB, Southern Han
Chinese, KHV and JPT) do not cluster tightly. The MDS plot
indicates that the Chinese and Vietnamese populations (CDX, CHB,
Southern Han Chinese and KHV) may be different from the
Japanese (JPT) population. While minimal, this Asian variability is
not novel and may be clinically significant when treating patients
of these ancestries.54 MDS plots of UGT2B7, ABCB1, OPRM1 and
COMT show considerably less between super-population cluster-
ing, specifically of the SAS, EUR and AMR populations, suggesting
that differences in these genes may be somewhat associated to
super-populations. MDS plots of ~ 15 000 polymorphisms do not
show sub-population clustering with their respective super-
populations. This observation may be explained by the extreme
allele frequency differences between sub-populations of the same
super-population. For example, the OPRM1 SNP, rs66579098, has
alternate allele frequencies of 0.27, 0.33, 0.52 and 0.78 in the PUR,
CLM, MXL and PEL sub-populations, respectively (belonging to the
AMR super-population).26,55
Tests for pairwise LD of damaging, or likely damaging,
polymorphisms in all five genes showed association between
polymorphisms from all genes. The rs677830 (OPRM1) and
rs5885589 (ABCB1) account for a substantial percentage of
significant pairwise LDs in the AFR, EAS, EUR and SAS populations.
These significant LDs may be clinically relevant due to the
potential for multilocus interactions.44 To our knowledge,
rs677830 and rs5885589 have not been reported as causal
polymorphisms. Interactions between these loci, or others, may
be responsible for compensation when a damaging polymorph-
ism dramatically alters normal protein activity, as suggested by
Bartošová et al.56 and Barratt et al.57 with ABCB1 and OPRM1
polymorphisms shown to alter protein activity in vivo.
In conclusion, baseline population summary statistics are
presented on five genes involved in opiate metabolism that have
been implicated in phenotypic variability leading to idiosyncratic
responses in patients. This study demonstrates some genetic
association between CYP2D6 and UGT2B7, ABCB1, OPRM1 and
COMT that will be important for future pharmacogenetic studies
and combinatorial genetic approaches for patient care.
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